Just download free CAT-120 free pdf with test prep
Is it safe to say that you are searching for CA-Technologies CAT-120 real questions with genuine inquiries for the CA Application Performance Management Administrator Exam?. We give as of late refreshed and legitimate CAT-120 free pdf. We have gotten a major assortment of legitimate and state-of-the-art CAT-120 test prep inquiries from genuine CAT-120 tests. You should simply retain and step through the exam.
Exam Code: CAT-120 Practice test 2022 by Killexams.com team CA Application Performance Management Administrator CA-Technologies Administrator exam Killexams : CA-Technologies Administrator test - BingNews
Search resultsKillexams : CA-Technologies Administrator test - BingNews
https://killexams.com/exam_list/CA-TechnologiesKillexams : Point-of-Care Ultrasound Certification Academy to Host World Conference
Ultrasound leaders from around the world will gather virtually to help define thelatest innovations in point-of-care ultrasound
ROCKVILLE, Md., Aug. 8, 2022 /CNW/ -- The global point-of-care ultrasound (POCUS) community, consisting of numerous specialties of healthcare providers, will gather virtually to expand and share their knowledge and experience with ultrasound at POCUS World Conference 2022 on September 16-17. Sponsored by Inteleos™, a non-profit community of medical professionals united in helping people gain the highest quality healthcare, the virtual conference will feature speakers from around the world to share best practices in POCUS education, application and certification.
The theme for this year's conference is Imaging as Innovation: Transforming Patient Care Through Point-of-Care Ultrasound. POCUS World 2022 attendees will have access to multiple learning and collaboration opportunities, including:
Networking opportunities through participating in a global POCUS community event.
Access to valuable POCUS knowledge through sessions focused on clinical applications, trends and technologies, education, and diversity, equity and inclusion.
Mentorship opportunities through coaching and training sessions with experienced POCUS professionals.
Engagement with top industry leaders who will provide insight into the latest and greatest POCUS trends including software development, artificial intelligence, and simulation solutions.
Attendees will also have the opportunity to hear from renowned POCUS professionals during various keynote addresses throughout the two-day conference. Highlights include a presentation on the latest developments in the field of lung ultrasound from Associate Professor, University of Trento (Italy) and founder of Ultrasound Lab Trento, Libertario Demi. Hospitalist physician, entrepreneur, and author of The POCUS Manifesto, Dr. Larry Istrail, will deliver a presentation on expanding the limits of physical exams through the use of point-of-care ultrasound and Dr. Lisa Rotenstein will provide insights on how to mitigate the effects of burnout in the healthcare industry and provide practical steps for improving the wellbeing of healthcare workers.
"We are excited to bring together some of the best global minds in POCUS to this year's virtual event," said Dale R. Cyr, CEO of Inteleos. "The POCUS Certification Academy™ and Inteleos are committed to expanding the knowledge and practical application of point-of-care ultrasound around the world. We believe POCUS World will help prepare and equip professionals to learn and deliver unprecedented patient diagnosis, care, and safety while using point-of-care ultrasound."
Healthcare professionals, educators, administrators, and students interested in attending POCUS World can register here: https://cvent.me/E3odgm
About Inteleos Inteleos™ is a non-profit certification organization that delivers rigorous assessments and cultivates a global community of professionals dedicated to the highest standards in healthcare and patient safety. Inteleos is the overarching governance and management organization for the American Registry for Diagnostic Medical Sonography® (ARDMS®) the Alliance for Physician Certification & Advancement™ (APCA™) and the Point-of-Care Ultrasound Certification Academy™ (POCUS™) which together represents over 124,000 certified medical professionals throughout the world. The Inteleos Foundation represents the philanthropic efforts for the organization.
"If the potential is there to make six figures, then you can put this career on your list and then decide out of all the careers that have this type of earning potential which one(s) you are most interested," according to Cheryl Palmer, a certified career coach and owner of Call to Career.
Specialist physicians are those who practice a specific branch of medicine. Medical specialties run the gamut from anesthesiology, cardiology and dermatology to neurology, orthopedics and radiology.
The Bureau of Labor Statistics (BLS) lists physicians and surgeons as the highest-paid occupation in its database, with anesthesiologists earning the most with an average salary of $271,440.
To pursue this career, you'll have to complete four years at the undergraduate level following a pre-med course of study, then four more years of medical school. There are also several more years of residency, possibly followed by a fellowship for one to three years.
If you're after a career that's lucrative and growing, add psychiatry to your list for a future job search. Although the BLS projects just 3% growth between 2020 and 2030, the average salary exceeds $200,000. These professionals diagnose and treat mental illnesses through the use of medication, counseling and hospitalization.
As with other health specialties, you'll have to complete medical school and a residency program, then pass a licensing test and gain board certification to practice as a psychiatrist.
Family and General Practitioner
A family physician has patients they treat on a regular basis for routine visits as well as common illnesses. The BLS projects an overall 5% job growth for family and general physicians between 2020 and 2030, which equals 6,700 added jobs.
According to the ACP, family medicine education encompasses the care of children and training in areas typically provided in other specialties. These physicians also complete medical school and a residency program following their undergraduate program.
Prosthodontists provide advanced care for dental and facial disorders. While some specialize in cosmetic dentistry, others focus on reconstructive services that restore or replace missing and damaged teeth.
General dentists need a doctoral degree from an accredited dental program and must pass written and clinical exams to qualify for a state license to practice. specialists like prosthodontists complete additional training via a multi-year residency.
Oral and Maxillofacial Surgeon
The BLS lists oral and maxillofacial surgery as one of the highest-paying occupations. These professionals provide reconstructive mouth, jaw, neck and dental surgery and treatment. The more experienced surgeons make approximately $231,276 a year, according to Payscale.
After completing a bachelor's degree, there are four years of dental school and an oral residency program that can range from four to six years. The six-year route involves a medical degree, according to the American Student Dental Association.
U.S. News & World Report has ranked orthodontics as one of the best fields for pay, growth, stress and work-life balance. These professionals fix bite and teeth alignment issues by designing retainers, braces and other mouth appliances for patients -- and are paid more than $200,000 a year on average.
Orthodontists spend a little more time training than general dentists do before they can practice. In addition to an undergraduate degree, orthodontists must go to dental school, followed by two to three years of additional education in an orthodontic residency program and a state licensing exam.
Top executives like CEOs earn well into the six figures. The big paycheck does come with added responsibility. CEOs oversee entire organizations and make sure they are reaching their goals. Opportunities are expected to grow 8% between 2020 and 2030.
Traditionally, many CEOs have a bachelor's degree in business administration or an MBA. However, this isn't the only way to make it to the top. Some top executives advance from lower-level management positions and can substitute experience for education, according to the BLS.
For fewer years in school than it takes to be an anesthesiologist but still phenomenal pay, you can opt to be a nurse anesthetist. People in this profession provide anesthesia care and oversee patient recovery from anesthesia. The BLS reports a higher than average growth outlook at 45%.
It takes at least approximately eight calendar years of education and experience to prepare for a career as a nurse anesthetist, according to the American Association of Nurse Anesthetists. Requirements typically include at least a master's degree in nursing, registered nurse licensure, at least one year of acute-care experience in an emergency room or intensive care unit, plus completion of an accredited nurse anesthesia program and passing the national certification exam.
Physicist, Ambulatory Care Health Services
Physicists look at the ways matter interacts with energy. In an ambulatory care health setting, medical physicists work with radiation technologies and treatments, often specializing in a particular area such as diagnostic medical physics or nuclear medical physics.
Before you can enjoy the luxuries this high-paying career can provide, you'll first undergo rigorous training. Medical physicists need a bachelor's degree in physics or another physical science and a master's degree in physics, medical physics or a related field, plus a residency prior to sitting for an test to earn board certification, according to the Mayo Clinic College of Medicine and Science. Some medical physicists go on to earn doctoral degrees.
Natural Sciences Manager, Research and Development in the Physical, Engineering and Life Sciences
Natural sciences managers oversee scientists tasked with activities related to research and development. Projects they manage might deal with manufacturing processes, expanding scientific knowledge or product development, according to the BLS, which notes that demand for these roles is expected to grow 6% between 2020 and 2030.
Natural sciences managers are usually promoted from roles as scientists. In addition to several years of experience as a scientist, managers generally have at least a bachelor's degree in a science field, although many have a master's or Ph.D.
Petroleum Engineer, Management of Companies and Enterprises
The top 10% of petroleum engineers make more than $208,000, according to the BLS. These workers find ways to extract oil and gas to meet the nation's needs. The demand and pricing for oil will create new job opportunities for petroleum engineers, with the BLS anticipating an 8% growth from 2020 to 2030.
A bachelor's degree in petroleum engineering is preferred, although other engineering specialties are acceptable in some instances. Cooperative-education programs also are encouraged to get class credit and on-the-job experience in the field.
Sales Manager, Finance and Insurance
A sales manager oversees an organization's sales team, establishing territories, training sales representatives and setting sales goals. The highest-paid sales managers work in the finance and insurance industry.
To work as a sales manager, you'll likely need a bachelor's degree in addition to a proven track record as a sales rep. Job growth is expected to be about as fast as average for all occupations over the coming years, with 7% growth anticipated from 2020 to 2030.
Airline Pilot, Copilots and Flight Engineers
Airline pilots, copilots and flight engineers are responsible for transporting people and things via airplane, helicopter or other aircraft. The highest-paid are airline pilots, who work in the scheduled air transportation industry, as opposed to commercial pilots, who fly unscheduled flights. Across both specialties, the highest 10% of pilots earned over $208,000 in 2020.
Job prospects for pilots are good, with the BLS projecting 13% growth from 2020 to 2030. To become an airline pilot you'll generally need a bachelor's degree as well as a commercial pilot's license and an Airline Transport Pilot certificate. Most airline pilots start their careers as commercial pilots.
A promising job future and exceptional pay, including being one of the highest-paid jobs around, make dentistry a hot field to pursue. Dentists keep teeth looking their best by treating tooth decay, cavities, gum problems and more. The demand for dentists is growing, particularly with more studies showing the link between proper dental care and overall health. In fact, job openings are expected to be plentiful, with 7% growth from 2020 to 2030, according to the BLS.
It takes time and commitment to pursue this hot career, however. After college, you have to attend dental school and pass state licensing exams. Dentists in specialized fields must take part in a residency program.
Computer and Information Systems Manager, Information
Computer information systems managers, also referred to as information technology managers, are accountable for organizations' computer-related activities, from determining technology goals to implementing and securing systems. Although many industries employ computer and information systems managers, the highest-paid work in the information industry.
The top 10% of earners are making more than $208,000 on average. What's great about this career is that it doesn't require years in school. A bachelor's degree in computer or information science and related work experience is typically sufficient, but many do go on to earn a graduate degree, notes the BLS.
Computer Systems and Information Manager, Computer Systems Design and Related Services
As more and more organizations require professionals to coordinate computer activities, the demand for computer systems and information managers is expected to grow 11% from 2020 through 2030. While those who work in systems design and related services earn over $9,000 less, on average than their information-industry counterparts, their salaries exceed $150,000 by a comfortable margin, and they have better-than-average opportunities for new positions.
Financial Manager, Professional, Scientific and Technical Services
Financial managers are responsible for the planning and directing of accounting, investing and other financial activities for companies. The average pay might be lower than other hot jobs on the list, but the top 10% of financial managers earn more than $208,000. Jobs in this occupation are growing much faster than average -- with 17% growth expected from 2020 to 2030, in fact. Top earners work in the professional, scientific and technical services industries.
These professionals generally hold a bachelor's degree in finance, accounting, business administration or economics, as well as five or more years of related experience. Today, employers prefer those with a master's degree in a related subject, according to the BLS.
Astronomer, Federal Government
Astronomers study celestial bodies like planets and stars, design equipment, devise theories and design and conduct scientific experiments. Some astronomers study distant galaxies and phenomena like black holes, whereas others track space debris that could interfere with satellites, according to the BLS. A number of industries, including research and development as well as colleges, universities and technical schools, hire astronomers; however, those who work for the federal government earn significantly more.
The job outlook for astronomers is about average for all occupations, with 8% growth expected from 2020 to 2030. To prepare for a job in federal government, you'll need a bachelor's or master's degree. Positions in business and academia generally require a Ph.D.
Lawyer, Federal Government
Lawyer pay varies by specialty and area, but the top 10% of earners overall make more than $208,000, according to the BLS, and your best opportunity to join their ranks is a job with the federal government. The job outlook is also good, with employment expected to grow 9% overall, keeping it in line with the national average for all occupations.
Another positive to this high-paying career is that becoming a lawyer doesn't require the amount of schooling it does to become a doctor. After earning a college degree, prospective lawyers must complete three years of law school and pass their state's bar exam.
Marketing Manager, Advertising/PR
The top 10% of marketing managers earn more than $208,000 on average, according to the BLS. The job involves planning and coordinating marketing programs for organizations, identifying customers and overseeing product development. On average, marketing manager jobs in the advertising and public relations industry pay significantly more than those in corporate management, information or wholesale trade.
Those choosing to pursue this career path have an optimistic job outlook, with the BLS projecting 10% growth between 2020 and 2030. Most marketing managers have a bachelor's degree in marketing, communications, business or a similar field, as well as work experience.
Mon, 01 Aug 2022 11:00:00 -0500en-CAtext/htmlhttps://ca.finance.yahoo.com/news/20-hot-jobs-pay-more-230001080.htmlKillexams : Master of Science in Business Analytics
Spring 2023 applications open August 1, 2022.
For additional information, please contact: Claire Goldsby, M.A. Admissions Coordinator firstname.lastname@example.org (916) 278-2895
International students will not be issued an F-1 student visa for this program as it is a completely online program.
Sacramento State’s Master of Science in Business Analytics (MSBA) prepares students to connect data and models to substantive business problems so effective business decisions can be made. This 100% online program focuses on using quantitative approaches and core technologies to help Improve decision making and performance in business. Covered approaches and their application to business disciplines such as accounting, finance, human resources, insurance, management, and marketing include:
Data visualization tools and techniques
Big Data technologies
Through a series of ten 3-unit courses (30 total units), The MSBA utilizes online course materials to deliver instruction in a completely web-based format allowing for considerable flexibility and the ability for students to focus on taking only two courses at a time while completing their degree in only 21 months.
MSBA graduates will:
Master, integrate, and apply knowledge and skills of business analytics to current and practical contexts and situations.
Demonstrate skills in business analytics software, tools, and technologies.
Demonstrate an ability to translate data and analytics into clear and actionable business decisions and insights.
Communicate analytics findings to business decision makers in a variety of formats appropriate to the audience.
Demonstrate the ability to think creatively, analytically, and critically when confronted with business problems.
The MSBA will prepare its graduates for data analytics related positions such as:
• Program Requirements (24 units) • Electives (6 units)
Program Requirements (24 units)
MSBA 201 Programming for Business Analytics (Python, R)
MSBA 202 Data Management for Business Analytics (SQL)
MSBA 203 Data Visualization and Communication for Business Analytics (Tableau)
MSBA 204 Decision Analytics (Python, R)
MSBA 205 Data Analytics for Business (Python, R)
MSBA 206 Data Mining for Business (Python, R)
MSBA 207 Machine Learning for Business (Python, R)
MSBA 208 Capstone Project in Business Analytics
Electives (6 units)
MSBA 211 Marketing Analytics
MSBA 212 Social Media Analytics
MSBA 213 Financial Analytics
MSBA 214 Big Data Technologies for Business
Note: MSBA 203 is the Graduate Writing Intensive (GWI) course that fulfills the first step of your Graduate Writing Assessment Requirement (GWAR). To complete the first step of the Graduate GWAR, all graduate students must earn a grade of B or higher in the required GWI course. More information can be found here.
Students should enroll in two courses each semester. Synchronous work will be scheduled one evening (6:00pm - 8:50pm) per week for each course. For each semester, students can expect to meet two nights per week.
Does not include student fees books and all course materials
Financial Aid may be available for students pursuing the MSBA degree. We recommend starting the financial aid process as early as possible by completing the Free Application for Federal Student Aid (FAFSA). More information can be found here.
For questions, please contact: email@example.com
MSBA Application Information
Spring 2023 Application opens August 1, 2022
Fall 2022 applications are now closed. Spring 2023 applications open August 1, 2022. We encourage early applications as applicants are admitted on a first come, first served basis.
Application Deadline for all applicaiton materaisl for Spring 2023: December 1, 2022
NOTE: You must complete the entire application process and pay the $70 fee by the appropriate deadline to be considered an applicant to the program. Incomplete applications will not be reviewed.
Please follow the directions carefully below to be considered for the MSBA Spring 2022 program. Applicants will need to submit the following:
On the first page, please select which term you would like to apply to: Spring 2023
Campus: Sacramento State Add Program: Business Administration - Business Analytics listed under "Sacramento Extension"
- Complete the Personal Information, Academic History, and Supporting Information Sections - Under Program Materials, applicants will submit the following:
Statement of Career Objectives (1 page): This statement should include a description of your long- and short-term career goals, and the ways in which you believe the MSBA degree will help you to achieve them.
Request for two letters of recommendation: Applicants will enter name and an email request will automatically be sent to the recommender on your behalf. Please advise your recommender to look for this email in their inbox, as well as their spam or junk-mail folder, as emails do occasionally get filtered out. Recommenders can complete the Recommendation Form or write their own letter and upload directly through the email portal. Please see page 27 of these instructions for more details on the recommendation submission process.
Copies of official transcripts from all colleges and universities attended, other than Sacramento State sent electronically to firstname.lastname@example.org or hard copy to:
Office of Graduate Studies California State University, Sacramento Riverfront Center, Room 215, MS 6112 6000 J St. Sacramento, CA 95819
All transcripts must be received by the application deadline. For students graduating in Fall 2022, please request official transcripts to be sent. You will need to request a second set of transcripts once you have graduated and your degree is conferred.
An email will be sent to you approximately one week after you submit your Cal State Apply application. The email will come from the University Office of Graduate Studies and contains instructions on how to create a SacLink account and Sac State email address.
MSBA Minimum Qualifications
Candidates are required to have:
Undergraduate degree from an accredited institution with a 2.50 overall GPA (Title V requirement)
Minimum 6 units of quantitative courses, with a grade of a minimum of “C” or higher in these quantitative courses from those applicants with less than 3 years of analytics related work experience.
Applicants who earned a degree from an institution located in a nation where English is not the official language, or where the language of instruction at that institution was not English, must take the TOEFL or IELTS or PTE and receive a passing score: a minimum TOEFL of 550 (paper-based) or 80 (Internet-based), or an IELTS score of 6.5
Two Letters of recommendation
Statement of Career Objectives (1 page): This statement should include a description of your long- and short-term career goals, and the ways in which you believe the MSBA degree will help you to achieve them.
MSBA Degree Learning Goals
Students will have certain capabilities (knowledge, skills, abilities) that result from your business degree program. At the Sacramento State, we call these capabilities learning outcomes. Learning outcomes are measured and analyzed through a broad range of assessments, from class assignments to standardized exams, to provide assurance of learning in the degree program. From time to time, the College of Business (COB) or your instructors may ask or require you to participate in assessments. We use the information from assessments to reinforce what is working or to make changes to support student learning and success. For example, we may revise curriculum or hire additional staff and faculty to support the needs of our students. We document how our students perform and the actions that we take to continuously improve. This process helps to enhance the student experience and maintain our external accreditation with AACSB International. Speaking of accreditation, less than 5% of business schools worldwide are accredited by AACSB and thus this elite accreditation contributes greatly to the COB reputation. We hope that when you are asked to participate in assessment activities that you will accept the invitation and put your best effort forward.
Goal 1: Integrate and apply knowledge and skills of business analytics.
1.1: Integrate knowledge of business analytics methods in statistics, data warehousing, data mining, machine learning, and management science to create business value.
1.2: Develop tools using business analytics software and technologies.
Goal 2: Communicate analytics findings to business decision makers.
2.1: Communicate in writing analytics findings to business decision makers appropriate to the audience.
2.2: Communicate analytics findings orally to business decision makers appropriate to the audience.
Goal 3: Demonstrate creative and analytical thinking.
3.1: Develop analytical models to appropriate data to make holistic judgments when analyzing business situation.
3.2: Demonstrate knowledge and understanding of the underlying assumptions and limitations of business analytics methods and models.
Goal 4: Communicate key knowledge of business analytics with clarity and purpose.
4.1. Demonstrate an ability to integrate multiple sources of data, evaluate data accuracy and thereby translate data and analytics into clear and actionable business decisions and insights.
Goal 5: Understand professional integrity and the ethical and legal implications of the use of business analytics.
5.1. Integrate ethical actions and regulatory compliance in the management and use of data.
Goal 6: Incorporate multicultural perspectives and global awareness
6.1. Develop business analytics implementations that represent multicultural perspectives and global awareness.
Min Li, PhD Faculty Director (916) 538-2753 Tahoe Hall - Room 2056 email@example.com
Sun, 31 Jul 2022 12:01:00 -0500entext/htmlhttps://www.csus.edu/college/business-administration/graduate/ms-business-analytics.htmlKillexams : NAPCO Security Technologies Awarded School Security Project for Pepperdine University
AMITYVILLE, N.Y., June 1, 2022 /PRNewswire/ — NAPCO Security Technologies, Inc. (NASDAQ: NSSC), one of the leading designers and manufacturers of high-tech electronic security devices, wireless subscription communication services for intrusion, fire alarm, access control and locking systems as well as a leading provider of school safety solutions, today announced that its products have once again been selected for use in a school security project at Pepperdine University in Malibu, CA.Pepperdine has approximately 9,500 students enrolled at its Malibu, CA. campus
The project includes the installation of NAPCO’s Alarm Lock division ArchiTech locks in the university’s classrooms. ArchiTech Series Networx Locks are an ideal access control solution, elegantly blending advanced wireless access control convenience within any décor, in an attractive, infinitely customizable designer locking form factor, in choice of trims and finishes. Ideal for educational, commercial office or multi-dwelling residential settings, these stylish, durable locks, leveraging proven Trilogy Networx™ access control technology, offer a choice of ID credential technology, and can be used to control access, a door at a time, across a wireless network, or as an integral part of a new or existing enterprise security system—spanning a few, or thousands of doors, in one building, a campus or multiple sites around the world. The Architech locks combined with NAPCO’s Continental Access division CA4K software, controls all of the doors for an enterprise class access control solution.
Richard Soloway, CEO of NAPCO commented, “We are pleased to report this school security project at Pepperdine University, which has used NAPCO products in multiple projects over the years. The security of our schools remains a very important issue, as we continue to witness horrific events around the country. NAPCO continues to be a leader in school security products and solutions, and we would like to thank Pepperdine for continuing to choose our products and being a highly valued customer.”
About NAPCO Security Technologies, Inc.
NAPCO Security Technologies, Inc., is one of the world’s leading manufacturers and service providers of high-tech electronic security devices as well as a leading provider of school safety solutions. The Company consists of four Divisions: NAPCO, plus three wholly-owned subsidiaries: Alarm Lock, Continental Instruments, and Marks USA. Headquartered in Amityville, New York, its products are installed by tens of thousands of security professionals worldwide in commercial, industrial, institutional, residential and government applications. NAPCO products have earned a reputation for innovation, technical excellence and reliability, positioning the Company for growth in the multi-billion dollar and rapidly expanding electronic security market. For additional information on NAPCO, please visit the Company’s web site at http://www.napcosecurity.com.
Safe Harbor Statement This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, but are not limited to, statements relating to the impact of COVID-19 pandemic; the growth of recurring service revenue and annual run rate; the introduction of new access control and locking products; the opportunities for fire alarm products; and our ability to execute our business strategies. actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those risk factors set forth in the Company’s filings with the Securities and Exchange Commission, such as our annual report on Form 10-K and quarterly reports on Form 10-Q.Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot ensure future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and the Company undertakes no duty to update such information, except as required under applicable law.
Director of Investor Relations
NAPCO Security Technologies, Inc.
800-645-9445 x 374
Mobile: 516-404-3597 firstname.lastname@example.org
Fri, 15 Jul 2022 20:04:00 -0500entext/htmlhttps://www.campussafetymagazine.com/news/napco-security-technologies-awarded-school-security-project-for-pepperdine-university/Killexams : The Cambridge World Prehistory
The Cambridge World Prehistory provides a systematic and authoritative examination of the prehistory of every region around the world from the early days of human origins in Africa two million years ago to the beginnings of written history, which in some areas started only two centuries ago. Written by a team of leading international scholars, the volumes include both traditional courses and cutting-edge approaches, such as archaeolinguistics and molecular genetics, and examine the essential questions of human development around the world. The volumes are organised geographically, exploring the evolution of hominins and their expansion from Africa, as well as the formation of states and development in each region of different technologies such as seafaring, metallurgy and food production. The Cambridge World Prehistory reveals a rich and complex history of the world. It will be an invaluable resource for any student or scholar of archaeology and related disciplines looking to research a particular topic, tradition, region or period within prehistory.
Sat, 03 Apr 2021 15:44:00 -0500entext/htmlhttps://www.cambridge.org/core/books/cambridge-world-prehistory/11AFB49A4D3B374F4FDD2AA9E99E5CA0Killexams : Healthcare in Metaverse Market Projected to be Worth USD 5,373 Million by 2030 at a 48.3% CAGR - Report by Market Research Future (MRFR)
Increasing Usage of Digital Twins in Healthcare to Boost Healthcare in Metaverse Market Growth
New York, US, Aug. 08, 2022 (GLOBE NEWSWIRE) -- According to a comprehensive research report by Market Research Future (MRFR), “Healthcare in Metaverse Market Analysis by Component, By Technology, By End-User (Hospitals, Pharmaceutical, Insurance Companies, Others) - Forecast 2030” valuation is poised to reachUSD 5373 Million by 2030, registering an 48.3% CAGR throughout the forecast period (2020–2030).
Healthcare in Metaverse Market Overview
Metaverse in mental health can be used to treat a variety of conditions, including phobias, anxiety disorders, PTSD, hallucinations, & delusions. Technology has transformed how we ask for assistance from coworkers, friends, family, or medical professionals when we are experiencing a mental breakdown. Since virtual reality technology possesses the potential to enhance human wellbeing, businesses in the industry are creating mental health apps for the metaverse.
Healthcare in Metaverse Market Report Scope:
Market Size in 2020
USD 504.8 Million
Market Size By 2030
USD 5373 Million
48.3% CAGR From 2024 to 2030
2020 to 2030
Brainlab AG, Novarad, GE Healthcare, Siemens Healthineers, Meta Platforms Inc., Nvidia, Microsoft, Roblox, Medtronic, Zimmer Biomet, Veyond Metaverse, gameChange VR, Sesame Care, PlushCare, Intuitive Surgical, BioFlight VR, CAE Inc., EON Reality Inc., ImmersiveTouch Inc., Medical Realities, Augmedics, Aimedis B.V., ARBREA LABS, and Wellx.ai
Increasing Usage of Digital Twins in Healthcare to Boost Market Growth
The increasing usage of digital twins in healthcare will boost market growth over the forecast period. In the field of medicine, digital twins can gather enormous amounts of patient scan data (such as MRI, CT, and ultrasound scans) over the time & combine it to one perspective to plan treatments and monitor the progression of diseases and their treatment. There are already several instances where human body prototypes, healthcare systems, or entire hospitals are in use. For instance, researchers at EMPA have already built several hundred avatars of real patients with chronic pain and are using them to foresee and optimize the effects of drugs. Through digital tracking and human body modeling, the use of digital twins in healthcare is revolutionizing clinical operations & hospital administration.
Privacy of Patient Data to act as Market Restraint
The privacy of patient data and the soaring cost of hardware and high-tech devices may act as market restraints over the forecast period.
Increasing Cost of Higher Advanced Digital Healthcare Infrastructure to act as Market Challenge
The increasing cost of higher advanced digital healthcare infrastructure may act as a market challenge over the forecast period.
Healthcare in Metaverse Market Segments
The global healthcare in metaverse market is bifurcated based on end user, application, technology, and component.
By component, hardware will lead the market over the forecast period.
By technology, augmented reality will dominate the market over the forecast period.
By application, the healthcare in metaverse market is segmented into Patient Engagement, Pre-Operation & Post-Operation Planning, Immersive 3D Training, 3D Lectures, VR Therapy, Remote Monitoring, and Others.
By end user, the healthcare in metaverse market is segmented into Hospitals, Pharmaceutical, Insurance Companies, and Others.
Browse In-depth Market Research Report (100 Pages) on Healthcare in Metaverse Market:
North America to Lead Healthcare in Metaverse Market
The metaverse industry is expected to benefit most from North America. The US, Canada, & Mexico make up this region. The primary factors fueling market growth are the growing importance of fusing the online and offline worlds, as well as the growing acceptance of mixed reality. In order to enhance their business processes, several companies in the region are heavily using sophisticated virtual reality, augmented reality technologies, and 3D simulation. From a corporate intelligence perspective, technologies like Extended Reality, 5G, & AI might make metaverse futuristic. The projection period is expected to be led by North America.
It is due to the region's significant concentration of metaverse-focused businesses, the quick development of healthcare infrastructure, the incorporation of AR and VR platforms in healthcare industry, the growth of investments in AR goods and services, and improvements in software and hardware. Due to the rapid expansion of the healthcare infrastructure and the use of digital technology, North America currently controls the metaverse in healthcare sector. The market is also expanding on account of the considerable number of metaverse technology-focused businesses in the area.
APAC to Have Admirable Growth in Healthcare in Metaverse Market
Due to the rising use of the internet & other technologies to merge the digital and physical worlds, the Asia-Pacific metaverse market is anticipated to expand at the quickest rate. For the purpose of enhancing the application of talents growing different trends across several organizations in China, Japan, & India, mixed reality is gaining momentum and attractiveness. The use of metaverse solutions in the region has grown as a result of regional firms' increasing need to compete with the western counterparts. As a result of its developments in healthcare technology, Asia Pacific is expected to grow at the quickest rate during the projection period. Along with significant investment in integrating this technology with the medical equipment, collaborations between metaverse technology businesses and the healthcare sector are further accelerating expansion.
Almost every business on earth has been impacted by the COVID-19 pandemic. As a result, the effect on the healthcare industry is substantial. With the Covid-19 outbreak, telemedicine, or the provision of medication as in the like of a remote service, has gained popularity in the healthcare industry. Only 43 percent of healthcare facilities were able to provide patients remote therapy prior to 2020. Today, the proportion is 95%. Physicians and nurses have found that they can diagnose many of the minor disorders that make up maximum caseload via video call or phone more quickly and efficiently. These routine consultations do not require a physical examination (or can be completed visually). There is little doubt that this will continue in metaverse.
Virtual reality, a key technology that enables the next-level immersion which designates a platform or application as a member of the metaverse, however, presents a completely new range of opportunities. Anyone who has used it understands that virtual reality headset experiences offer a much greater sense of "being there" over other virtual environments like websites, messaging services, or social media.
White Box Server Market: By Form Factor, Business Type, and Processor, Operating System – Global Forecast till 2030
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis regarding diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
CONTACT: Market Research Future (Part of Wantstats Research and Media Private Limited) 99 Hudson Street, 5Th Floor New York, NY 10013 United States of America +1 628 258 0071 (US) +44 2035 002 764 (UK) Email: email@example.com Website: https://www.marketresearchfuture.com
Mon, 08 Aug 2022 00:21:00 -0500en-CAtext/htmlhttps://ca.finance.yahoo.com/news/healthcare-metaverse-market-projected-worth-122100949.htmlKillexams : Certiport Names 2022 Microsoft Office Specialist World Champions
The winners of the 2022 Microsoft Office Specialist (MOS) World Championship have been announced by Certiport, the leading provider of performance-based IT certification exams that accelerate academic and career opportunities for learners.
SALT LAKE CITY, July 27, 2022 /PRNewswire-PRWeb/ -- The winners of the 2022 Microsoft Office Specialist (MOS) World Championship have been announced by Certiport, the leading provider of performance-based IT certification exams that accelerate academic and career opportunities for learners.
In its 20th year, the competition attracted more than one million contestants from around the world. Students, ages 13 to 22, competed with peers to prove their superior skills in Microsoft Word, Excel, and PowerPoint, culminating in the most popular technology skills competition on Microsoft Office—and the only one endorsed by Microsoft since its inception in 2002.
To enter the competition, students took a qualifying Microsoft Office Specialist certification test to demonstrate their mastery of Microsoft Office technology. Regional competitions were held worldwide, and 95 finalists qualified to compete in the final round of competition held in Anaheim, CA from July 24-27.
The 2022 MOS World Champions are:
Microsoft Word (Microsoft 365 Apps and Office 2019)
First place: Gabriel Stanciu, Romania
Second place: Trong Khai Nguyen, Vietnam
Third place: Chen Yuen Wong, Hong Kong
Microsoft PowerPoint® (Microsoft 365 Apps and Office 2019)
First place: Tristan Pesqueira, USA
Second place: Mihail Iliev, Bulgaria
Third place: Himanish Angrish, Canada
Microsoft Excel® (Microsoft 365 Apps and Office 2019)
First place: Duy Phong Nguyen, Vietnam
Second place: Nikolaos Rapanis, Greece
Third place: Heero Ramadhana Sipayung, Indonesia
Microsoft Word (Office 2016)
First place: Rohan Matthias Vargas, Ireland
Second place: Ching Chi Tsao, Taiwan
Third place: Ngoc Tung Chi Dao, Vietnam
Microsoft PowerPoint® (Office 2016)
First place: Cong Minh Bui, Vietnam
Second place: Benjamin Rands, USA
Third place: Amanda Gabriela Castillo Diaz, Mexico
Microsoft Excel® (Office 2016)
First place: Ondrej Cach, Czech Republic
Second place: Andrew Chuang Saladin, USA
Third place: Nicolas Stigler Yanez, Peru
In the concluding round, competitors participated in a two-part skills demonstration. The first skills demonstration was a 30-minute timed exam. The second part is an advanced three-hour research project, in which students research their given topic, formulate an opinion, and represent their conclusions and research in an asset appropriate to the competition application (Word report, Excel workbook, or PowerPoint presentation). This is the second year where finalists were required to complete a free-form project.
At the final event in Anaheim, Certiport and Microsoft recognized the top student competitors in the MOS World Championship Awards Ceremony and presented each First place winner with a $7,000 cash prize, Second place with $3,500 and Third place with $1,500.
"The pandemic put our live MOS Championship events on hold. We are so thrilled to be able to return to in-person competitions," said Ray Murray, Vice President and General Manager, Certiport. "It is inspiring to see students from 21 countries come together to 'speak Microsoft'. The winners receive extra praise, but every single student who entered has earned a valuable workforce credential that will help them find success in college and in their career. The last two years have highlighted the importance of IT skills for tomorrow's professionals and it's incredible to see so many young people get introduced to IT certifications through the MOS World Championship."
Microsoft Office Specialist is the only official Microsoft-recognized certification for Microsoft Office globally and serves as a powerful instrument for assessing students' skills and preparing them for real-world application of their knowledge.
"The Microsoft Office Specialist World Championship is one of our favorite events annually, because these students are thrilled to compete and they inspire all of us with their competitive spirit and crowning achievement," said Rick Herrmann, Vice President Worldwide Public Sector, Education, Microsoft. "These students work diligently to earn valuable industry-recognized certifications, and we know that the future is bright with upcoming business and technology leaders like those we met at the MOS World Championship."
Next year, Certiport will host the 2023 Microsoft Office Specialist World Championship at Orlando, Florida, from July 30-August 2, 2023.
See what our competitors and other news outlets are saying by searching the event hashtag #MOSWC on Facebook and Twitter.
Certiport, a Pearson VUE business, is the leading provider of certification test development, delivery and program management services delivered through an expansive network of over 15,000 Certiport Authorized Testing Centers worldwide. Certiport manages a sophisticated portfolio of leading certification programs including: the official Microsoft Office Specialist certification program, the Microsoft Certified Fundamentals certification program, the Microsoft Certified Educator program, the Adobe® Certified Professional certification program, the Autodesk Certified User certification program, the Intuit certification program, the App Development with Swift certification program, the Unity Certified User certification program, the Communication Skills for Business certification program, the IC3 Digital Literacy certification, and the Entrepreneurship and Small Business certification program. Certiport reliably delivers over three million tests each year throughout the secondary, post-secondary, workforce, and corporate technology markets in 148 countries and 26 languages worldwide. For more information visit http://www.certiport.com or follow Certiport on Twitter at http://www.twitter.com/certiport. "Certiport" is a registered trademark of NCS Pearson, Inc. in the United States and other countries. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.
Thu, 28 Jul 2022 09:21:00 -0500en-UStext/htmlhttps://finance.yahoo.com/news/certiport-names-2022-microsoft-office-221500403.htmlKillexams : CNL Partners With ARC Canada to Advance Fuel Development
CHALK RIVER, Ontario, July 27, 2022 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, is pleased to announce that it has entered into a collaboration agreement with ARC Clean Energy Canada (ARC Canada), a New Brunswick-based team working to develop and licence its sodium-cooled advanced small modular reactor (SMR) technology. Funded through CNL's Canadian Nuclear Research Initiative (CNRI), the agreement includes work to advance the fuel development and manufacturing processes to produce fuel for ARC Canada's advanced small modular reactor technology.
"Fuel development is a particular strength of the team here at the CNL," commented Dr. Jeff Griffin, Vice-President of Science and Technology. "We have supported the fuel development for Canadian heavy water reactor technology since its inception back in the 1950's; we continue to support the fuel needs of low-power and research reactors across Canada and the globe; and, and in recent years, we have been investing and growing our capabilities in small modular and advanced reactor technologies and fuels. This exciting new CNRI project will benefit from this experience, helping ARC Canada move their product closer towards commercialization, while enriching our skill set for supporting this growing industry into the future."
As Canada's national nuclear laboratory, Canadian Nuclear Laboratories (CNL) is uniquely qualified to efficiently manufacture and test nuclear fuel at its Chalk River Laboratories site. Our Fuel Development Laboratories fabricate reactor fuel concepts and prototypes and evaluate their performance under a variety of simulated reactor conditions. Both pellet- and pin-type fuel – similar to those used in the ARC Canada technology are fabricated, and CNL is able to further support the work through on-site analytical capabilities including non-destructive examination, metallographic and ceramographic examination, mechanical testing, thermal and physical property measurements, and analytical chemistry.
"This is a significant first step towards establishing capability in Canada to manufacture fuel assemblies for the ARC technology," said Dr. Maggie Manley, Fuel Systems Engineer, leading the project for ARC Canada. "Our collaboration with CNL, with access to their world-class facilities and qualified technical experts, is critical to validate our fuel qualification program and deployment approach. ARC Canada is proud to have been selected to partner with our national laboratories as we work towards a clean energy future."
The ARC Canada technology is an advanced small modular reactor, designed to produce 100 MW of electrical energy; enough to power a small city. The ARC Canada technology is based on a proven design, using sodium coolant and a metallic uranium-zirconium alloy fuel enabling operation at near-atmospheric pressure which produces high quality steam for electrical generation and industrial processes. Among the many objectives of the CNRI project, CNL will work in partnership with ARC Canada to establish the capability to fabricate the metallic uranium sodium bonded fuel pins using surrogate fuel material. While the focus for this initial CNRI agreement is on a pilot system, the work will result in a qualified set of procedures for the development of a full production line to support the Canadian fleet.
Launched in 2019, the CNRI program was established by CNL to accelerate the deployment of SMRs in Canada by enabling research and development, and connecting the SMR industry with the facilities and expertise within Canada's national nuclear laboratories. Among the many benefits of the program, participants optimize resources, share technical knowledge, and gain access to CNL's expertise to help advance the commercialization of SMR technologies.
The next call for CNRI proposals is expected to be released later this year. For more details on the program, please visit www.cnl.ca/CNRI.
Canadian Nuclear Laboratories is a world leader in nuclear science and technology offering unique capabilities and solutions across a wide range of industries. Actively involved with industry-driven research and development in nuclear, transportation, clean technology, energy, defence, security and life sciences, we provide solutions to keep these sectors competitive internationally.
With ongoing investments in new facilities and a focused mandate, Canadian Nuclear Laboratories is well positioned for the future. A new performance standard reinforced with a strong safety culture underscores every activity.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to Improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.
Wed, 27 Jul 2022 03:18:00 -0500text/htmlhttps://www.benzinga.com/pressreleases/22/07/g28227357/cnl-partners-with-arc-canada-to-advance-fuel-developmentKillexams : The three pillars of bioentrepreneurship
History has proven that starting a new biotechnology company is not an activity for the faint of heart. Neither is it an endeavor that can be undertaken without patience, perseverance, or optimism at their extremes. However, no matter how strong your character, there are three structural elements that are absolutely necessary for biotechnology success. We call these the "three pillars" of bioentrepreneurship: a quality management team, adequate financing, and access to new technology that leads to products.
While establishing these pillars to support your company is difficult, maintaining them over time is an even bigger challenge. Each of these pillars must function in synergy over periods of up to 10 years or longer and, by retrospective analysis, it is clear that any weakness within the first critical decade will determine the future of the entrepreneurial biotechnology company. Because most companies do not achieve "first–tier" status if they have a demonstrable weakness in one of the three pillars, the importance of each of these structures within the context of the industry warrants independent examination.
The management pillar is the first to be secured in any new biopharmaceutical company. No transformation of technology opportunity into product sale can ever occur without skilled managerial capability. However, having said this, there is a sobering truth to be addressed: A chief executive officer and management team equipped to run a biotechnology company from startup through commercialization are one of the scarcest resources in the industry. Consequently, management is often the weakest pillar in most biotechnology companies.
This is largely because the repertoire of managerial skills required to navigate the company successfully from startup through full integration is so wide ranging. Take, for example, the startup. The company's earliest management team may consist of only a scientific founder and a businessperson. During that period, the critical managerial skill sets include the ability to direct a research and development organization and the ability to communicate the company's promise to the financial community.
If a company succeeds through the initial phases and begins commercial operation, the next set of management skills it must acquire, either internally or externally, are manufacturing and commercialization capabilities. At the same time, managerial focus should also be directed toward collaboration as the company positions itself for growth.
Since few biotechnology companies in the early stages of development can internally develop a full range of operating capabilities, the precise nature of these relationships, and the timing of their implementation, must be carefully managed for their impact on the company. Marketing and sales agreements, in particular, critically affect the profit and loss statement, and the unfavorable timing of their execution can have a lasting negative effect on the bottom line.
While all of these deals are being developed, the judicious allocation of resources within the company is a managerial imperative at all times. There are numerous examples of companies that have commercialized products well but, absent sufficient internal investment in R&D, have inadequately fueled their product pipelines. Conversely, other management teams have built impressive R&D enterprises but have failed to bring a single product to commercial fruition.
From this sketch of typical managerial responsibilities during the building of a company, it is quite apparent that the set of skills a startup company's very existence may depend on will become significantly less important to the enterprise 10 years down the road. The appropriate allocation of corporate resources, as the company transitions from an R&D–driven to a market–driven culture is a lasting managerial challenge that heavily taxes all management teams.
Capital forms the second pillar of any biotechnology company. It is unequivocally true that, at the early stages, a biotechnology company can never have too much of this resource. Undercapitalization and a weak CEO are the root causes of most biotechnology company failures. Being opportunistic in the marketplace when financial windows are open is advice that cannot be taken too liberally.
Therefore, bioentrepreneurs must spend considerable energies on cultivating financial resources for their young companies. Perhaps the best advice on the general subject of capitalization was offered to me in the early 1980s by Bill Hambrecht, (Hambrecht & Quist, New York), a venerable figure in the biotechnology financial sector. "When the cookie jar comes around," he said, "grab as many cookies as you can—you don't know when it will come around again."
This advice is especially true today when launching a biotechnology company requires many multiples of what it cost in the 1980s. When one considers that it costs, on average, over $300 million to develop a single product, and first–tier companies have had to raise $600 million or more before gaining operating profitability, grabbing lots of cookies of different flavors, shapes and sizes becomes an economic imperative.
Although many biopharmaceutical companies are launched through private investment, venture capital leading to the initial public offering is the more common route by which emerging companies acquire growth financing. It can be a treacherous road for shareholders. Conventional wisdom holds that the several rounds of financing required to capitalize a new biotechnology company will undesirably dilute shareholder interest. Further dilution occurs through the initial public offering, a transaction that is ultimately necessary to bring the company to full operating profitability. In the end, however, dilution is never the issue. Raising sufficient capital is the issue. The word "dilution" should be struck from lexicon of biotechnology–speak, particularly as it relates to relatively young companies; undue concern over dilution discourages the taking of appropriate financial risk.
The corporate partnership offers another option to reinforce a company's capital pillar. A biotechnology company, often lean on resources and experience but long on technology assets, is a logical partner for an established pharmaceutical company. Large pharmaceutical companies, frequently clamoring for new product candidates, bring both development and regulatory expertise, as well as cookies—a.k.a. money—to the table. An early agreement with a large pharmaceutical company can provide financial stability and facilitate the commercialization of the product, providing a significant reduction in risk for the young biotechnology company.
The major downside of this relationship, if a product candidate is successfully developed in the context of such an arrangement, is that the new company may only receive a modest royalty on the product's sales. If the biotechnology company has the capital to wait until it has invested in the product's development and clinical trials, it is in a stronger position to capture a larger share of product sales. This maneuver does, however, expose the company to greater risk.
The mid–1970s emergence of technologies based on recombinant DNA and monoclonal antibody technologies, which evolved from the revolutionary work of scientific partnerships such as that of Cohen and Boyer, and Kohler and Milstein, established the foundations for the biotechnology industry. This is the third pillar upon which every company must be built. Today, most biotechnology companies still look first to academia for sources of new technology. Academia provides a particularly fertile ground for harvesting such discoveries, the importance of which cannot be minimized. Most of the experts in either emerging technologies or disease areas reside here. The Bayh–Dole Act, legislation that encourages academic institutions to license discoveries that emanate from federally funded research, will most likely continue to fuel the biotechnology revolution.
Virtually from its inception, every biotechnology company must have a well–defined and well–articulated product focus. Whether directed toward a specific technology or toward a disease area, the company needs a clear vision of its basis for future revenues. What is unique to biotechnology in this regard is that a single product or two may be sufficient to create the foundation for a large, profitable company. The great challenge for any bioentrepreneur in this time of astonishing opportunity is to maintain a rigorous focus on the chosen product and its underlying technology.
If we consider, for example, that the recombination of DNA and the production of monoclonal antibodies are biotechnology's first and second technology "platforms,"—still viable for product development today—then gene–splicing leading to genomics and gene therapy represent the third technology platform. Already the temptation to abandon well–conceived product development strategies based on the first two generations of technologies in favor of the third generation platform technologies is evident. The explosion of activity in genomics is a clear example of this. Relinquishing otherwise viable products based on earlier technology platforms in favor of those based on nascent discoveries will ensure a long lapse in the introduction of new products.
With today's biopharmaceutical products based exclusively on first and second platform technologies, we must consider the industry as a whole to be in its infancy. But we have far from exhausted the reservoir of potential products to be developed from those early technologies. Third platform technologies applied to knowledge we glean from the role of specific genes in various disease states will, over the course of the next 20 years, create innumerable opportunities to develop beneficial products. Many of these will form the technology pillar of generations of new companies.
In the United States today, approximately 2,000 biotechnology companies employ about 130,000 people. Of these, approximately 300 companies are publicly held and 1,700 are private. About $65 billion has been invested in biotechnology to date. Taken together, the market value of all companies is approximately $110 billion1. Thus, overall financial returns in this industry can be described as modest to good.
If one gauges the success of these companies through product sales, profitability (earnings per share), and market value fewer than a dozen have been identified as truly successful. These dozen companies, each with market valuations in excess of $1 billion, have been categorized as first–tier companies by the investment community. If achieving first–tier valuation defines success, then this represents a true success rate of <1% for the formation of new biotechnology companies during the period from 1975 to 1998—a sobering statistic.
But statistics are statistics, and market value is not the only measure of achievement. If, for example, one uses as the benchmark of success an internal rate of return of at least 10%, then biotechnology's success rate is much higher—closer to 60%. Why? Financial achievement is often the result of acquisition, merger, early initial public offerings, off–balance sheet financing, and other creative financial structures such as sale of part of the company.
The curious fact about biotechnology is that many companies have delivered adequate investor returns without developing or marketing products. This arsenal of financial gymnastics has also proven extremely useful in making the industry nearly bulletproof. So far, there have been only two bankruptcies industry–wide. Biotechnology's often–discussed low success rate must then be tempered by the understanding that in this industry a company's progression to product sales and profitability is often preempted by terminal financial transactions.
We live in a society with an insatiable demand for increasingly sophisticated health care that must be provided more cost effectively than ever before. Reforms in the healthcare delivery system have forever altered how we think about new product development. Biotechnology companies are uniquely capable of responding to the pharmacoeconomic imperatives of today's healthcare marketplace.
The product development efforts of tomorrow's biotechnology companies will be science–driven and aimed at early diagnosis, disease prevention, and improved therapeutics. Using the tools of biotechnology, therapies can now be developed at the gene and molecular levels that will provide us with better, more specific, and less costly products. The emergence of genomics, the process by which genes are linked to specific diseases, is one example of this new direction.
However, as compelling as the opportunities may be, the challenges associated with translating them into meaningful commercial products will remain daunting. Bioentrepreneurs who can build a company grounded on the three pillars of management, capital, and technology, will provide the next generation of "successes" in biotechnology's rapidly evolving history.boxed-text
Box 1: Case study: Centocor
Centocor began operations in 1979 by developing diagnostic products based on monoclonal antibody technology. Much of this technology had been licensed from The Wistar Institute, a scientific research institution located in Philadelphia. In order to maximize its scientific relationship with Wistar, the company established its laboratory facilities nearby at the University City Science Center. Within four years, Centocor had created a profitable business, having developed such cancer diagnostic products as CA–19–9, CA–125, and CA–15–3. In his role as head of the diagnostics division, David Holveck, present chief executive officer, advanced the growth of the business to a level of approximately $40 million per year.
In 1986, Centocor embarked on a new journey in biotechnology. With a successful diagnostics business anchoring its position in the marketplace, Centocor repositioned itself as a biotechnology company. Through the aggressive pursuit of licenses for new discoveries from academic institutions, Centocor amassed a rich coffer of potential product candidates. Both 17–1A, or Panorex, and HA–1A, or Centoxin, were evaluated as the company's first biotechnology products, but it was Centoxin that emerged as the initial launch candidate.
Centoxin was a human antibody whose primary application was in the treatment of sepsis resulting from Gram–negative bacterial infection. A devastating condition leading to irreversible organ failure, sepsis accounts for nearly 80,000 deaths per year. Centoxin acted on the root cause of mortality: It neutralized the endotoxin produced by Gram–negative bacteria. Early work by Ziegler et al.2 suggested the potential utility of a polyclonal antibody mixture in the treatment of sepsis. Further in vitro studies with Centoxin demonstrated the increased effectiveness of the monoclonal antibody, and these results provided the impetus to develop the drug.
With a study design identical to the favorable polyclonal study, a clinical trial was initiated to establish unequivocally the efficacy of the Centoxin in the treatment of sepsis. The company positioned itself for success by investing early in a commercial infrastructure, including manufacturing, marketing, and sales. Despite an endorsement by a US Food and Drug Administration (FDA; Rockville, MD) advisory panel, Centocor did not receive FDA approval for this product on the basis of its single clinical trial. The second trial, requested by the FDA to clarify certain results, ultimately failed.
Centoxin's regulatory defeat was a cataclysmic event for Centocor. In selecting its product candidate, Centocor missed an important cue from the medical marketplace: Sepsis had become an increasingly complex disease. It was found to result, not only from a complex cascade of biochemical events, but also from infection originating from multiple sources—including Gram–negative bacteria, viral, and fungal sources.
Further complicating this picture was the fact that new immunosuppressive drugs, which had become a therapeutic mainstay in oncology and transplantation medicine, were a significant factor in multiple infections. Without a highly specific diagnostic test to establish the infectious agent responsible for the sepsis, a single therapy was not predicted to succeed. The difficulty in developing sepsis therapies is illustrated by the fact that 20 clinical trials, conducted by other pharmaceutical companies and academic institutions subsequent to Centocor's trial, also met with failure.
At the time the FDA required the second Centoxin clinical trial, the company's position was financially perilous. Its stock had dropped from a previous high of $60 per share in December 1991 to $6 by April 1992. And with a cash burn rate of about $50 million per quarter supporting the corporate infrastructure and its 1,600 employees, few resources remained with which the company could rejuvenate.
It was decisive action taken by the board of directors during the spring of 1992 that ultimately saved the company. Holveck was appointed president. He was issued a directive to reduce cash burn to the lowest possible level. The head count was reduced from 1,600 to 600. We enlisted the indispensable assistance of Michael Wall, then an emeritus member of the board, in managing Wall Street, and we negotiated a sales and marketing agreement with Eli Lilly (Indianapolis, IN) to help commercialize Centoxin, in the event of its ultimate approval, and ReoPro, our second biotechnology product under development. After several lean and very challenging years, Centocor began to rebuild. The internal R&D operation was reorganized and reenergized for its critical role in driving the company's technology capabilities. Monoclonal antibodies, recombinant DNA–based products, and DNA–based products were used to fill the product pipeline.
While Centoxin was never ultimately approved, with the support of Lilly, Centocor did receive FDA approval of ReoPro in 1994, and the product's success has paved the way for Centocor's achievement of operating profitability in late 1996. Lilly has proved to be a superb commercialization partner in both very difficult and very good times. The success of this collaboration, in which the sales and marketing expertise of a pharmaceutical giant were coupled with the product development and clinical trial experience of its technology–oriented partner, confirmed Centocor's decision to capitalize on similar relationships in commercializing its other products.
Centocor entered into a partnership with Glaxo Wellcome (London) for the commercialization of Panorex, a treatment for colorectal cancer that has received approval in Germany. Avakine, our biotechnology product for Crohn's disease, is currently under review at the FDA, and is in final stages of clinical development for the treatment of rheumatoid arthritis. Avakine will be sold directly by Centocor in the US and by a corporate partner in Europe and Japan.
Most recently, we have made our first product acquisition, Retavase, a clot–buster product that we believe will be synergistic with ReoPro. We also expect that Retavase, along with ReoPro, will secure Centocor's position in the acute cardiovascular therapy market.
Today, Centocor is in its best financial and scientific position since it was founded 19 years ago. We are a stronger, but more humble, company. During the coming years, our challenge is to grow revenues, increase profits, and remain innovative.
Thu, 10 Mar 2022 11:21:00 -0600entext/htmlhttps://www.nature.com/articles/nbt0598supp_13Killexams : Centre for Educational Excellence
Hello! I’m delighted to be a part of the EAL Initiatives Team with the Centre for Educational Excellence to support the teaching and learning community here at SFU. I first started working with multilingual learners in the last century, when I spent a year in Japan teaching students who ranged in age from 3 to 92. I then taught English language test preparation courses for a year in Greece, before moving to Canada and teaching in the private and then public sectors. My non-teaching experiences have included online and f2f teacher training, program management and administration, course and workshop design and delivery, conference presentations, and language coaching.
I have an undergraduate Arts degree from the University of Glasgow (my hometown), and a Master of Education in TESL from the University of Southern Queensland in Australia. Additionally, I have a Graduate Certificate in Online Education and Training from the University of London’s Institute of Education, and a Certificate in Electronic Publishing and Graphic Design from VCC. I’ve presented locally, nationally, and internationally at conferences in Canada, the US and the UK. I’ve been an active member of the BC Teachers as an Additional Language Association for many years, and was honoured with their Lifetime Contributor Award in 2015.
I generally enjoy learning and practicing new skills, as experiencing the perspective of a student informs my work in language education. I’m interested in the application of the coaching approach to language learning and teaching, and in the potential for new and emerging technologies in the field.